Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Cyclical Evolution of the Global Right.

Chase-Dunn C, Grimes P, Anderson EN.

Can Rev Sociol. 2019 Nov;56(4):529-555. doi: 10.1111/cars.12263.

PMID:
31743608
2.

Racial and Ethnic Differences in Self-Assessed Facial Aging in Women: Results From a Multinational Study.

Alexis AF, Grimes P, Boyd C, Downie J, Drinkwater A, Garcia JK, Gallagher CJ.

Dermatol Surg. 2019 Dec;45(12):1635-1648. doi: 10.1097/DSS.0000000000002237.

PMID:
31702594
3.

Safety and Effectiveness of VYC-17.5L for Long-Term Correction of Nasolabial Folds.

Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V.

Aesthet Surg J. 2019 Jul 26. pii: sjz200. doi: 10.1093/asj/sjz200. [Epub ahead of print]

PMID:
31346621
4.

In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream

Grimes PE, McDaniel DH, Wortzman M, Nelson D.

J Drugs Dermatol. 2019 Jul 1;18(7):642-648.

PMID:
31329402
5.

Myths and Knowledge Gaps in the Aesthetic Treatment of Patients With Skin of Color

Alexis AF, Few J, Callender VD, Grimes P, Downie J, Boyd C, Gallagher CJ.

J Drugs Dermatol. 2019 Jul 1;18(7):616-622.

PMID:
31329382
6.

Polymethylmethacrylate Collagen Gel-Injectable Dermal Filler for Full Face Atrophic Acne Scar Correction.

Joseph JH, Shamban A, Eaton L, Lehman A, Cohen S, Spencer J, Bruce S, Grimes P, Tedaldi R, Callender V, Werschler P.

Dermatol Surg. 2019 Dec;45(12):1558-1566. doi: 10.1097/DSS.0000000000001863.

PMID:
30829754
7.

New oral and topical approaches for the treatment of melasma.

Grimes PE, Ijaz S, Nashawati R, Kwak D.

Int J Womens Dermatol. 2018 Nov 20;5(1):30-36. doi: 10.1016/j.ijwd.2018.09.004. eCollection 2019 Feb.

8.

Comparison of 311-nm Titanium:Sapphire laser and 308-nm excimer laser treatment for vitiligo: A randomized controlled non-inferiority trial.

Bae JM, Eun SH, Lee HN, Kim GM, Grimes PE, Lee JH.

Lasers Surg Med. 2019 Mar;51(3):239-244. doi: 10.1002/lsm.23048. Epub 2019 Jan 25.

PMID:
30681166
9.

A closer look at the role of the dermatologist in championing total women's health through the dermatology gateway.

Grimes PE.

Int J Womens Dermatol. 2018 Nov 15;4(4):189-192. doi: 10.1016/j.ijwd.2018.09.006. eCollection 2018 Dec.

10.

International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation.

Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, Lim HW, Elbuluk N, Bhatia B, Tovar-Garza A, Nahhas AF, Braunberger T, Ezzedine K.

Br J Dermatol. 2019 Mar;180(3):574-579. doi: 10.1111/bjd.17013. Epub 2018 Oct 5.

PMID:
30030843
11.

Vitiligo: Patient stories, self-esteem, and the psychological burden of disease.

Grimes PE, Miller MM.

Int J Womens Dermatol. 2018 Jan 8;4(1):32-37. doi: 10.1016/j.ijwd.2017.11.005. eCollection 2018 Mar.

12.

Safety and Effectiveness of the Hyaluronic Acid Dermal Filler VYC-17.5L for Nasolabial Folds: Results of a Randomized, Controlled Study.

Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, Lin V, Murphy DK.

Dermatol Surg. 2018 May;44(5):670-678. doi: 10.1097/DSS.0000000000001529.

13.

Considerations When Treating Cosmetic Concerns in Men of Color.

Awosika O, Burgess CM, Grimes PE.

Dermatol Surg. 2017 Nov;43 Suppl 2:S140-S150. doi: 10.1097/DSS.0000000000001376. Review.

PMID:
29064976
14.

The Role of Diet and Supplements in Vitiligo Management.

Grimes PE, Nashawati R.

Dermatol Clin. 2017 Apr;35(2):235-243. doi: 10.1016/j.det.2016.11.012. Review.

PMID:
28317532
15.

Depigmentation Therapies for Vitiligo.

Grimes PE, Nashawati R.

Dermatol Clin. 2017 Apr;35(2):219-227. doi: 10.1016/j.det.2016.11.010. Review.

PMID:
28317530
16.

Bimatoprost 0.03% Solution for the Treatment of Nonfacial Vitiligo.

Grimes PE.

J Drugs Dermatol. 2016 Jun 1;15(6):703-10.

PMID:
27272076
17.

Updates in the understanding and treatments of skin and hair disorders in women of color.

Grimes PE.

Int J Womens Dermatol. 2015 May 29;1(2):76. doi: 10.1016/j.ijwd.2015.05.001. eCollection 2015 Jun. No abstract available.

18.

Living with vitiligo: results from a national survey indicate differences between skin phototypes.

Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Ballanger F, Jouary T, Taïeb C, Taïeb A.

Br J Dermatol. 2015 Aug;173(2):607-9. doi: 10.1111/bjd.13839. Epub 2015 Jul 28. No abstract available.

PMID:
25892476
19.

Indications and limitations of afamelanotide for treating vitiligo-reply.

Lim HW, Grimes PE, Lebwohl M.

JAMA Dermatol. 2015 Mar;151(3):350. doi: 10.1001/jamadermatol.2014.4951. No abstract available.

PMID:
25607828
20.

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M.

JAMA Dermatol. 2015 Jan;151(1):42-50. doi: 10.1001/jamadermatol.2014.1875.

PMID:
25230094
21.

Histopathological progression of a mycosis fungoides mimic to classic vitiligo.

Kaskas NM, DiGiorgio C, Nicotri T, Hooper D, Grimes P.

J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1856-7. doi: 10.1111/jdv.12546. Epub 2014 May 12. No abstract available.

PMID:
24813942
22.

A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars.

Karnik J, Baumann L, Bruce S, Callender V, Cohen S, Grimes P, Joseph J, Shamban A, Spencer J, Tedaldi R, Werschler WP, Smith SR.

J Am Acad Dermatol. 2014 Jul;71(1):77-83. doi: 10.1016/j.jaad.2014.02.034. Epub 2014 Apr 13.

PMID:
24725475
23.

Novel skin brightener used as monotherapy for moderate melasma in skin of color.

Grimes PE.

J Drugs Dermatol. 2014 Mar;13(3):364-6.

PMID:
24595584
24.
25.
26.

The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.

Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW.

JAMA Dermatol. 2013 Jan;149(1):68-73. doi: 10.1001/2013.jamadermatol.386.

PMID:
23407924
27.

Surgical reconstruction of nasal sarcoidosis: a case report.

Lesavoy MA, Shirvanian VN, Grimes P.

Ann Plast Surg. 2010 Jun;64(6):800-2. doi: 10.1097/SAP.0b013e3181b4051b. Review.

PMID:
20489410
28.

Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.

Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, Shalita A, Glaser DA, Grimes P, Webster G, Barnett P, Le Gall N.

J Drugs Dermatol. 2010 May;9(5):549-58.

PMID:
20480800
29.

Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method.

Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, Nordlund JJ, Rendon M, Taylor S, Gottschalk RW, Agim NG, Ortonne JP.

J Am Acad Dermatol. 2011 Jan;64(1):78-83, 83.e1-2. doi: 10.1016/j.jaad.2009.10.051. Epub 2010 Apr 15.

PMID:
20398960
30.

Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.

Grimes PE, Bhawan J, Guevara IL, Colón LE, Johnson LA, Gottschalk RW, Pandya AG.

J Am Acad Dermatol. 2010 Jun;62(6):962-7. doi: 10.1016/j.jaad.2009.06.067. Epub 2010 Apr 15.

PMID:
20398959
31.

A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen.

Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR.

Br J Dermatol. 2010 Mar;162(3):647-54. doi: 10.1111/j.1365-2133.2009.09436.x.

32.

A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.

Bhawan J, Grimes P, Pandya AG, Keady M, Byers HR, Guevara IL, Colón LE, Johnson LA, Gottschalk R.

Am J Dermatopathol. 2009 Dec;31(8):794-8. doi: 10.1097/DAD.0b013e3181a9070d.

PMID:
19755910
33.

Safety and effectiveness of hyaluronic acid fillers in skin of color.

Grimes PE, Thomas JA, Murphy DK.

J Cosmet Dermatol. 2009 Sep;8(3):162-8. doi: 10.1111/j.1473-2165.2009.00457.x.

PMID:
19735512
34.

Six-month safety results of calcium hydroxylapatite for treatment of nasolabial folds in Fitzpatrick skin types IV to VI.

Marmur ES, Taylor SC, Grimes PE, Boyd CM, Porter JP, Yoo JY.

Dermatol Surg. 2009 Oct;35 Suppl 2:1641-5. doi: 10.1111/j.1524-4725.2009.01311.x. Epub 2009 Aug 25.

PMID:
19708876
35.

Postinflammatory hyperpigmentation.

Taylor S, Grimes P, Lim J, Im S, Lui H.

J Cutan Med Surg. 2009 Jul-Aug;13(4):183-91. Review.

PMID:
19706225
36.

Practical applications of genomics research for treatment of aging skin.

Kaczvinsky JR Jr, Grimes PE.

J Drugs Dermatol. 2009 Jul;8(7 Suppl):s15-8.

PMID:
19623780
37.

Management of hyperpigmentation in darker racial ethnic groups.

Grimes PE.

Semin Cutan Med Surg. 2009 Jun;28(2):77-85. doi: 10.1016/j.sder.2009.04.001. Review.

PMID:
19608057
38.

A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma.

Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, Hexsel D, Im S, Lim J, Lui H, Pandya A, Picardo M, Rendon M, Taylor S, Van Der Veen JP, Westerhof W.

J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1254-62. doi: 10.1111/j.1468-3083.2009.03295.x. Epub 2009 May 19.

PMID:
19486232
39.

A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.

Grimes PE, Shabazz D.

Dermatol Surg. 2009 Mar;35(3):429-35; discussion 435-6. doi: 10.1111/j.1524-4725.2009.01063.x. Epub 2009 Feb 22.

PMID:
19250310
40.

Phase 4 study to assess tretinoin pump for the treatment of facial acne.

Eichenfield LF, Nighland M, Rossi AB, Cook-Bolden F, Grimes P, Fried R, Levy S; PUMP Study Group.

J Drugs Dermatol. 2008 Dec;7(12):1129-36.

PMID:
19137766
41.
42.

Effects of human subjects requirements on classroom research: multidisciplinary evidence.

Lopus JS, Grimes PW, Becker WE, Pearson RA.

J Empir Res Hum Res Ethics. 2007 Sep;2(3):69-78. doi: 10.1525/jer.2007.2.3.69.

PMID:
19385853
43.

The safety of hydroquinone.

Nordlund J, Grimes P, Ortonne JP.

J Cosmet Dermatol. 2006 Jun;5(2):168-9. No abstract available.

PMID:
17173592
44.

The safety of hydroquinone.

Nordlund JJ, Grimes PE, Ortonne JP.

J Eur Acad Dermatol Venereol. 2006 Aug;20(7):781-7. Review.

PMID:
16898897
45.

Confusions about color: formulating a more precise lexicon for pigmentation, pigmentary disorders, and abnormalities of "chromatics".

Nordlund JJ, Ortonne JP, Cestari T, Grimes P, Chan H.

J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S291-7. No abstract available.

PMID:
16631970
46.

Increasing our understanding of pigmentary disorders.

Grimes P, Nordlund JJ, Pandya AG, Taylor S, Rendon M, Ortonne JP.

J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S255-61. Review.

PMID:
16631966
47.

Community-based trial of a triple-combination agent for the treatment of facial melasma.

Grimes P, Kelly AP, Torok H, Willis I.

Cutis. 2006 Mar;77(3):177-84.

PMID:
16610738
49.

Microdermabrasion.

Grimes PE.

Dermatol Surg. 2005 Sep;31(9 Pt 2):1160-5; discussion 1165. Review.

PMID:
16176767
50.

Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma.

Grimes PE, Yamada N, Bhawan J.

Am J Dermatopathol. 2005 Apr;27(2):96-101.

PMID:
15798432

Supplemental Content

Loading ...
Support Center